Physician

Michael Zumwalt, M.D.

According to 2025 Medicare claims, Michael Zumwalt, M.D. (NPI: 1275947764) practices dermatology in the Carson City, NV market, with the plurality of this provider's patient population coming from Carson City, NV. This provider's primary affiliated billing organization is MOUNTAIN WEST DERM - BLACKHART PLLC (NPI: 1740633015; TIN: 813253496) and primary practice location at 89703-8457.

Zumwalt's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 797 traditional Medicare patients, billed 4,187 HCPCS/CPT codes, and received $1,120,477 in Medicare payments. The top billing code was 17311 (Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks). Part D data shows 1,105 prescription claims across 639 beneficiaries totaling $19,582 in drug costs, led by Fluorouracil (Fluorouracil). Open Payments data shows 58 records totaling $1,311. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $11,349 to $1,120,477. In contrast, Part D prescription costs started with an early spike, then settled into a lower baseline, moving from $126,624 to $19,582. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$571K$1.1M2017 Medicare payment: $11,349 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $233,993 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $645,160 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $1,141,458 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $1,120,477 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
2016N/RN/RN/R
201760228$11,349
2018N/RN/RN/R
2019N/RN/RN/R
2020N/RN/RN/R
20213302,229$233,993
20226488,010$645,160
20238624,301$1,141,458
20247974,187$1,120,477

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$63K$127K2017 Drug cost: $126,624 (USD; Tot_Drug_Cst)2018 Drug cost: $4,504 (USD; Tot_Drug_Cst)2019 Drug cost: $1,431 (USD; Tot_Drug_Cst)2020 Drug cost: $5,799 (USD; Tot_Drug_Cst)2021 Drug cost: $70,397 (USD; Tot_Drug_Cst)2022 Drug cost: $23,787 (USD; Tot_Drug_Cst)2023 Drug cost: $25,355 (USD; Tot_Drug_Cst)2024 Drug cost: $19,582 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015N/RN/RN/R
2016N/RN/RN/R
201777161$126,624
201865120$4,504
201985101$1,431
2020172236$5,799
2021332534$70,397
2022437787$23,787
20236171,039$25,355
20246391,105$19,582

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
17311Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks505697$403
17312Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks345721$322
13121Complicated repair of wound of scalp, arms, or legs, 2.6-7.5 cm250326$229
13132Complicated repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet, 2.6-7.5 cm256290$195
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more208253$63

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
FluorouracilFluorouracil1273,679$7,864
Doxycycline HyclateDoxycycline Hyclate7247,364$6,893
Clobetasol PropionateClobetasol Propionate19568$693
CephalexinCephalexin47470$605
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen86439$484

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.58$1,311ABBVIE INC.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Michael Zumwalt, M.D.?

Tedicare shows public-source Medicare data for Michael Zumwalt, M.D. (NPI 1275947764), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Michael Zumwalt, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Michael Zumwalt, M.D.?

Michael Zumwalt, M.D. is linked to MOUNTAIN WEST DERM - BLACKHART PLLC (billing NPI 1740633015) in the available physician profile data.

Does Michael Zumwalt, M.D. have Open Payments data?

Michael Zumwalt, M.D. has 58 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.